Kurzfassung

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in check point inhibitor naïve patient with locally advanced or metastatic non squamous Non-Small Cell Lung Cancer who progressed during or after first line platinum-based treatment